The aberrant activation of NF-κB pathway may result from different causative mechanisms, like inactivating mutations or deletions of IκBα in Hodgkin’s lymphoma[23], activating mutations of NF-κB2 gene in B- and T-cell lymphomas[23], amplifications and/or translocations of NIK in multiple myeloma[2]. The gene discussed is NFKB1; the disease is plasma cell myeloma.